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Tissues are the new frontier of discoveries in immunology. Cells of the immune system are an integral part of tissue physiology and
immunity. Determining how immune cells inhabit, housekeep, and defend gut, lung, brain, liver, uterus, and other organs helps
revealing the intimate details of tissue physiology and may offer new therapeutic targets to treat pathologies. The uterine
microenvironment modulates the development and function of innate lymphoid cells [ILC, largely represented by natural killer (NK)
cells], macrophages, T cells, and dendritic cells. These immune cells, in turn, contribute to tissue homeostasis. Regulated by ovarian
hormones, the human uterine mucosa (endometrium) undergoes ~400 monthly cycles of breakdown and regeneration from
menarche to menopause, with its fibroblasts, glands, blood vessels, and immune cells remodeling the tissue into the transient
decidua. Even more transformative changes occur upon blastocyst implantation. Before the placenta is formed, the endometrial
glands feed the embryo by histiotrophic nutrition while the uterine spiral arteries are stripped of their endothelial layer and smooth
muscle actin. This arterial remodeling is carried out by invading fetal trophoblast and maternal immune cells, chiefly uterine NK
(uNK) cells, which also assist fetal growth. The transformed arteries no longer respond to maternal stimuli and meet the increasing
demands of the growing fetus. This review focuses on how the everchanging uterine microenvironment affects uNK cells and how
uNK cells regulate homeostasis of the decidua, placenta development, and fetal growth. Determining these pathways will help
understand the causes of major pregnancy complications.
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INTRODUCTION
The decidua in humans and mice
The decidua is the specialized uterine mucosa that forms from the
endometrium under the influence of progesterone at the end of
each cycle in humans. The word decidua comes from the Latin
deciduous, meaning falling down or falling off. Indeed, the decidua
is shed after every menstrual cycle and after birth, when the
placenta is expelled (the placenta is also known as the ‘afterbirth’).
The cellular composition of the decidua includes stromal cells
transformed from fibroblasts, glands, and immune cells, mostly
cells of innate immunity, including ILCs (NK cells being the most
abundant) and macrophages, but also some cells of adaptive
immunity, including T, regulatory T (Tregs), and dendritic cells
(DCs). Innate immune cells populate also the mouse decidua,
which forms only in response to implantation and has a broadly
similar cellular composition in both species [1–3]. The decidua is
essential for healthy implantation and for the formation of the
placenta [4] as illustrated by ectopic pregnancies and placenta
creta or accreta [5]. Fetal trophoblast cells erode and invade the
decidua in both primates and rodents. In humans, fetal
trophoblast cells migrate through the decidua and up into the
muscle layer, known as myometrium. While the invasion is
shallower in mice, the type of placenta is haemochorial in both
species—and indeed in all primates and rodents—meaning that
the outermost fetal membrane called chorion bathes into the
maternal blood. This makes human and mouse placentas more
similar to each other than to those of other mammals such as
ruminants, horses, and pigs that have epitheliochorial placentas, in
which the fetal chorion remains separated by endometrial
endothelium, connective tissue, and uterine endothelium from
the maternal blood [6]. During decidualization and until the
placenta is fully formed, the extracellular matrix and vessels of the
endometrial stroma are remodeled [7]. How uNK cells and other
uterine immune cells reconcile their tissue-specific homeostatic
functions with their innate destructive potential is unclear and we
have discussed this in another recent review article [8]. Indeed,
uNK cells facilitate tissue remodeling, trophoblast invasion, and
feto-placental growth, but can also inflame and destroy tissues to
defend from pathogens. The potential conflict of interest of tissue
immune cells may be resolved by division of labor among
subgroups of uNK and ILCs, where some take up roles in
homeostasis and others in immunity. For instance, both humans
and mice have at least three subsets of uNK cells [1, 2] and in mice,
there is some evidence coming from gene expression studies that
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support this notion. For example, mouse tissue-resident uNK cells
may specialize in tissue remodeling, while other uNK cells
resembling peripheral NK cells and known as conventional NK
cells (cNK) may take up immune defense roles [9]. This review will
focus on uNK cells, while we have described more broadly uterine
ILCs in other article [10].
Misnomers and naming names in the extended NK cell family
When discovered in 1975, NK cells were appropriately named after
their innate killing instinct [11], but ‘killers become builders during
pregnancy’, was famously suggested in 2006 by Le Bouteiller and
Tabiasco [12] commenting on a landmark paper on human dNK cells
[13]. Thus, the name we use to refer to the most abundant immune
cell population in the uterus is effectively a misnomer. Nevertheless,
in an era of immunology when more immune cell subsets are
discovered and renamed than we can keep up with [14], it may be
wiser to resist the temptation of introducing new names and instead
perpetuate the misnaming for the sake of clarity (Table 1). NK cells
are the founding member of the ILC family, with the Lymphoid
Tissue inducer (LTi) cells discovered some 20 years after and other
ILCs from 2008 [15] onward. In this review ‘NK’ refers to all human
NK cells (universally CD3–CD56+, although there is a minor
CD56– NK cell subset) regardless of their tissue or species of origin.
Within these, ‘pbNK’ specifically indicates human peripheral
blood CD3–CD56+ ILCs, and ‘cNK’ indicates mouse spleen
CD3–NK1.1+CD49b(DX5)+ ILCs or cells that phenotypically match
them, e.g., cNK are found in mouse uterus and liver. Because human
pbNK and mouse cNK cells may be analogous functionally, also
human pbNK are sometimes called cNK. Every tissue has its
complement of NK cells, including fetal liver, bone marrow, thymus,
spleen, lymph nodes, brain, liver, salivary glands, kidney, pancreas,
and of course, uterus. By convention the name of NK cells in that
tissue is modified by including the first letter of the name of the
tissue, hence ‘uNK’ indicates either human CD45+Lin–CD56+ ILCs or
mouse CD45+Lin–NK1.1+NKp46+ ILCs found in cell suspensions
isolated upon digestion of uterine tissue (Table 2). This tissue comes
from either human voluntary pregnancy termination at 6–12 weeks
of pregnancy or dams culled at various gestational days (gd) and
mostly around mid-gestation (gd9.5), mouse pregnancy being
19–21 days, depending on laboratory strains. Because human uNK
cells are located in the mucosa, they are often referred to as
decidual NK cells (dNK). In mice, uNK cells are also found in the
myometrium, where they also specifically accumulate in a gestation-
specific structure called mesometrial lymphoid aggregate of
pregnancy (MLaP), which is embedded between the two layers of
smooth muscle, away from the invading trophoblast and surround-
ing the uterine artery branch that shoots through the uterus wall.
Because they are found both in the decidua and in the myometrium,
mouse uterine NK cells are more often referred to as uNK cells rather
than dNK cells. Accordingly, we will use dNK specifically for human
cells, while uNK may indicate cells of both species. Endometrial
(eNK) cells are intended as human or mouse uterine NK cells
extracted from the non-pregnant endometrium [16]. Human uNK
cells can be collected longitudinally and non-invasively from the
menstrual blood [17, 18]. These cells may be informative of their
tissue of origin, although one ought to be aware that they have
been exposed to physiological tissue breakdown prior to collection.
Uterine NK cells
NK cells represent the main member of the ILC family [19]. Five
main human CD45+Lin– CD56+ dILC subsets are currently
identified: decidual NK cells (dNK1, dNK2, and dNK3), ILC3s, and
proliferating NK cells (dNKp) [20]. In dILCs, dNK1 accounts for the
most abundant subset (55%), followed by dNK2 (~15%), and dNK3
(~15%). dNK1 express receptors including Killer-cell immunoglo-
bulin-like receptors (KIR), CD94/NKG2A, and LILRB1, indicating that
they particularly respond to HLA class I ligands, including maternal
HLA-A, -B, -C, and -E or fetal HLA-C, -E or -G, which are expressed
Table 1. NK cells in human (Hu) and mouse (Mo)
Name Phenotype Description
NK Hu CD3– CD56+ and Mo CD3– NK1.1+ ILC family member, found in blood, lymphoid tissues, and many organs
pbNK Hu CD3– CD56+ and Mo CD3– NK1.1+ CD49b
(DX5)+
Peripheral blood NK cells, including CD56dimCD16+ killers and CD56brightCD16− cytokine
producers
cNK Hu CD3– CD56+ and Mo CD3–NK1.1+ CD49b
(DX5)+
Conventional human CD56dimCD16+ or mouse CD3-NK1.1+DX5+ NK cells in blood or any
tissue, including spleen, uterus, and liver
dNK Hu CD45+ Lin– CD56+++ NK cells in human decidua
uNK Hu CD45+ Lin– CD56+++ and Mo CD45+ Lin–
NK1.1+ NKp46+
NK cells in human decidua (70% of all lymphocytes) and in mouse decidua or myometrium
(30% of all lymphocytes)
eNK Hu CD45+ Lin– CD56+++ Endometrial NK cells
Table 2. uNK cell subsets in the pregnant human (Hu) or mouse (Mo) uterus*
Name Phenotype Description
dNK1 Hu CD45+ Lin– CD56+++ CD49a+ KIRhi NKG2Ahi LILRB1hi CD39hi NK cells in human decidua (55%)
dNK2 Hu CD45+ Lin– CD56+++ CD49a+ KIRlo NKG2Ahi CD103lo NK cells in human decidua (15%)
dNK3/ieILC1 Hu CD45+Lin–CD56+++ CD49a+ CD69hi CD103hi NKG2Dhi
CD161hi KIRlo NKG2A+/– NKp44+/–
NK cells in human decidua (15%)
dNKp Hu CD45+ Lin–CD56+++ CD69lo Ki-67hi NKG2Ahi KIR+/– Proliferating human dNK cells (5%)
trNK Mo CD45+ Lin– NK1.1+ NKp46+ Tbet+ Eomes+ CD49a+ Mouse tissue-resident uNK cells (50%)
cNK Mo CD45+ Lin– NK1.1+ NKp46+ Tbet+ Eomes+ CD49b(DX5)+ Mouse conventional NK cells in the uterus (40%)
uILC1 Mo CD45+ Lin– NK1.1+ NKp46+ Tbet+ Eomes– CD49a+ Eomes– mouse tissue-resident uNK cells that resemble ILC1 in
other organs, e.g., the liver (10%)
*For more details on human dNK see ref. [10] and for mouse uNK see ref. [2]. Proportions and phenotypes of uNK cells and their subsets vary throughout the
menstrual cycle and in pregnancy in humans [21] as well as with puberty, pregnancy, and breastfeeding in the mouse [9].
F. Wang et al.
2102













by extravillous trophoblasts (EVT). Following stimulation, dNK2
and dNK3 secrete more cytokines and chemokines than
dNK1, including GM-CSF and XCL1, which can act on EVTs. The
relationship of these human dILCs to those in the mouse uterus is
still unknown. Three murine CD45+Lin– NK1.1+NKp46+ uILC
subsets are currently identified: Eomes+CD49a+ tissue-resident
NKs (trNK), Eomes– CD49a+ ILC1s (also tissue-resident), and
Eomes+CD49a– cNK [9]. Abundant in early pregnancy, trNKs
express factors that promote arterial transformation. cNKs expand
after placental development and secrete IFN-γ, while uILC1s
expand in subsequent pregnancies and express CXCR6, a memory
marker in other lymphocytes. Based on cell surface phenotype,
mouse uterine trNK cells share markers with human dNK1,
whereas mouse uterine cNK resemble contaminant CD16+ pbNK
found in the human uterus.
Proportions and phenotypes of uNK cells and their subsets vary
throughout the menstrual cycle and in pregnancy in humans [21]
as well as with puberty, pregnancy, and breastfeeding in the
mouse [9]. How these shifts are related to other dynamic changes
in the uterus during pregnancy is unclear. In humans, dNK cells
peak in frequency (~70% of the total lymphocytes) during the first
trimester and diminish in numbers midway through gestation.
Only small numbers of dNKs are present at term [22]. Compared to
the first-trimester dNKs, term dNKs show increased degranulation
toward K562 and upon PMA/ionomycin stimulation, reduced
cytotoxicity towards HCMV-infected cells, reduced HLA-C recogni-
tion, and distinct protein and gene expression profiles (Fig. 1). In
mice, the proportion of total uNK cells in the uterus is the highest
(~30% of the total lymphocytes) at mid-gestation and, within uNK
cells, trNK cells peak at gd5.5 to then decrease at mid-gestation,
when cNK cells increase. Like human dNK, also mouse trNK and
cNK cells decline during late gestation [9, 23].
dNKs are functionally and phenotypically unique compared to
other tissue NK cells or pbNKs. They display a distinctive
morphology with large granules, secrete a specific set of
chemokines, and express a unique combination of cell surface
markers [20]. Unlike pbNKs, dNKs are poorly cytotoxic as they are
unable to polarize granules to the immune synapse [22]. The poor
killing activity of dNKs is surprising given the size of the granules
(about triple the size of pbNK granules) [20], and their content,
with abundant perforin and granzyme B [24, 25]. Interestingly,
poorly cytotoxic pbNK cells of immunodeficient patients affected
by the Chediak-Higashi syndrome share some features with dNK
cells [26–29]. Rather than triggering cytotoxicity, the interactions
between dNK and EVT may activate the release of soluble factors
that promote maternal spiral artery transformation, which
increases blood, O2, and nutrients supply for the growing fetus
[30]. Further phenotypic differences between dNK and pbNK
include upregulated CD57, CD16, and DNAM-1 and
downregulated NKG2A on pbNK cells, which correlate with
increased KIR co-expression [31, 32]. In contrast, increased KIR
co-expression on dNK correlates with upregulated LILRB1, Ki-67,
NKp30, NKG2A, and downregulated NKG2D, CD161, and T-bet
[20]. 2B4 is co-activating in pbNKs, but inhibitory in dNKs [33], and
LILRB1 is inhibitory in pbNKs, but may activate dNKs [34]. These
differences illustrate the wide range of phenotypic and functional
features of dNK cells during pregnancy and due to the specific
uterine microenvironment. Deep phenotyping of eNK cells [35]
and comparisons between cells of women with a history of
healthy or complicated pregnancies may provide new biomarkers
to predict pregnancy disorders.
Development of uterine NK cells
We have discussed the current understanding of uNK cell
development in another review [10] and summarize the main
points here. While it is established that NK cells originate from
bone marrow precursors, one unanswered key question is
whether uNK cells derive from circulating CD34+ hematopoietic
progenitor cells (HPCs) or NK lineage-committed precursors that
migrate to the uterus. Following bone marrow transfer, NK cells
are detected in the uterus of both humans and mice, suggesting
that they can arise from transferred HPCs [36, 37]. Human NK-
committed precursors are found in blood and can differentiate
into mature NK cells in the response to IL-15 [38]. However, CD34+
progenitors are also found in the human uterus and can
differentiate into NK cells in vitro [39]. Therefore, bone-marrow-
derived NK precursors and stem cells resident in the uterus can
both contribute to uNK populations. Indeed CD56+ NK cells
develop in the human uterus xenografted into immunodeficient
mice, in response to steroid hormones [40]. Recent data from HLA-
mismatched uterus transplants show that uNK can derive from the
circulating cells [21]. Human pbNK cells also acquire features of
uNK cells when exposed to certain cytokines, including transform-
ing growth factor-β (TGF-β), suggesting that peripheral NK cells
also can contribute to uNK populations [41]. Parabiosis studies in
mice suggest that tissue-resident uNK cells proliferate during early
pregnancy, while recruitment of circulating NK cells increases uNK
cell numbers later in gestation [42].
HOMEOSTASIS
Interactions of uNK cells with decidual stroma cells (dSC)
Decidual stromal cells (dSC) regulate the unique immune
microenvironment of the decidua. This is brilliantly illustrated by
how mouse dSC epigenetically silence CXCL9 and CXCL10, thus
limiting T-cell recruitment to the decidua [43]. In a recent single-
cell RNA-sequencing analysis of the maternal-fetal interface, three
subsets of human stromal cells have been described: dS1, dS2,
Fig. 1 dNKs through the reproductive timeline.
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and dS3 [1]. dS1 and dS2 cells express IGF-1 and IL-15, respectively
[44, 45], suggesting that dS2 may promote the development of
dNK cells from CD34+ hematopoietic precursors present in human
decidua [39]. Producing interleukin-15 (IL-15) [46] and TGF-β1 [41],
dSC can significantly modulate the uterine immune microenvir-
onment. In vitro, TGF-β, IL-15, and IL-18 convert pbNK cells into
dNK-like cells by inducing the expression of CD9, CD49a, CD103,
CXCR3, and CXCR4 [41, 47], suggesting the possibility that at least
part of dNK cells originate from peripheral NK cells, [21]. In
addition to influencing the phenotype of NK cells and macro-
phages, dSC may also influence dNK function by downregulating
both cytotoxicity and secretion of IFN-γ, mainly through the
immunosuppressive action of TGF-β [48]. Secretion of IFN-γ is a
point of divergence between human and mouse uNK cells
because human uNK do not procude much IFN-γ while mouse
uNK cells do secrete it physiologically and actually IFN-γ is the key
cytokine driving the necessary vascular changes in murine preg-
nancy [49]. Within mouse uNK subsets, cNK cells are the main IFN-
γ producers, while trNK cells mainly produce homeostatic and
vaso-active factors [9, 50]. Nevertheless, human dNK cells can be
induced to produce IFN-γ upon culture in vitro [13] and a
population of pregnancy-trained dNK cells displays epigenetic
modification that eases translation of the IFNG gene [18].
Producing chemokines CXCL10/IP-10, CXCL11, and CXCL12 /SDF-
1, dSC attract NK cells by binding to receptors CXCR3 [51] and
CXCR4 expressed by pbNK and dNK3 [52]. dS2 and dS3 cells
express LGALS9 and CLEC2D, which bind TIM3 and KLRB1 on dNK
subsets. dS3 cells also express CXCL14 [1], which stimulates the
migration of NK cells binding to unknown receptors [53].
dSC may also contribute to dNK cell education, a process driven
by the interaction of inhibitory NK receptors with self MHC
molecules. While the specific biological significance of NK cell
education remains largely unknown, a comparison of dNK and
pbNK inhibitory NK repertoire and self-MHC reveals that NK
education operates differentially across tissues [54]. HLA-B
dimorphism at position -21 of the leader peptide encodes
either methionine (M) or threonine (T) which lead, respectively,
to high or low HLA-E expression, resulting in either strong (-21 M/
M or M/T) or weak (-21 T/T) NKG2A educators [55]. In women who
are genetically programmed to favor NKG2A ligation and
education, NKG2A was recently found as protective in pregnancy
as it is required for appropriate maternal vascular adaptation, fetal
growth, and normal placental gene expression [56]. Aberrant
placentation upon loss of NKG2A was confirmed by transcriptomic
studies revealing inadequate vasculature transformation and
perturbed gene expression pathways [56, 57]. Independent of
maturation status, NKG2A+ dNKs are more diverse and function-
ally responsive than NKG2A–counterparts [55, 56]. Finally,
NKG2A KO dams carried fetuses affected by asymmetric fetal
growth restriction (FGR). Taken together, these data demonstrate
that NKG2A education influences pregnancy outcomes.
Interactions of uNK cells with extravillous trophoblast (EVT)
Trophoblasts are specialized cells differentiating from fetal
extraembryonic tissues. They are indeed the first cells that
differentiate from the zygote, eventually forming the placenta
[58]. Essentially, human trophoblast can be divided into syncytio-
trophoblast, which forms the outer layer, and cytotrophoblast on
the inner side. Cytotrophoblast is further divided into villous
trophoblast, which forms the villi, and extravillous trophoblast
(EVT), which is made of cells that bud off the villi to replace
maternal endothelial cells or invade deep into the decidua and the
myometrium. Trophoblast invasion is shallower in mice,
where giant trophoblast cells are loosely analogous to human
EVT. First-trimester human EVT cells have a unique human
leukocyte antigen (HLA) repertoire, expressing the classical class
I molecule HLA-C, and non-classical HLA-E and HLA-G, whereas
HLA-A and HLA-B, and class II molecules HLA-DP, HLA-DQ, and
HLA-DR are absent. This unique MHC composition enables EVT to
modulate subsets of uNK cells, which express combinations of
cognate receptors for HLA-C (KIR2DL1, KIR2DS1, KIR2DL2, KIR2DL3,
KIR2DS4, and KIR2DS5), HLA-E (CD94/NKG2A and CD94/NKG2C),
and HLA-G (KIR2DL4 and LILRB1). Uterine arteries remodeling and
placentation are thought to be regulated by these interactions.
HLA-C expression is increased on human uterine stromal cells at
the onset of pregnancy. The KIR repertoire in dNKs is different
from endometrial eNK and pbNK cells, and the expression of HLA-
C binding KIRs on dNK increases during the first trimester [59].
HLA-C allotypes can be one of two groups depending on a single
amino acid residue on position 80 of the heavy chain: C1+HLA-C
allotypes have Lys while C2+HLA-C allotypes have Asn [60]. A
certain combination of maternal KIR and fetal HLA-C are
associated with pre-eclampsia and birth weight—immunoge-
netics of pregnancy complications has been reviewed previously
[60, 61]. Women with HLA-C2 have decreased expression of the
corresponding receptor, KIR2DL1, while women with HLA-C1 have
increased expression of the corresponding receptor, KIR2DL3 [54].
Interestingly, maternal HLA-C has no significant influence on
the expression of KIR2DL1 or KIR2DL3 in pbNK cells [54]. These
findings suggest that the mechanisms that determine
the repertoire of dNK and the effect of self-MHC on NK education
may differ in uNK cells compared with pbNK. HLA-E serves as the
ligand of the inhibitory receptor CD94/NKG2A and its activating
counterpart CD94/NKG2C. HLA-G interacts with KIR2DL4 and
LILRB1 [62]. In particular, HLA-G is a dimeric form only expressed
by the EVT and its derived peptides allow greater HLA-E
expression, thus influencing binding strength to CD94/NKG2A.
Additionally, HLA-G can trigger the secretion of cytokines,
proangiogenic factors, and growth factors from dNK cells by
interacting with KIR2DL4 [63]. Specific dNKs can acquire HLA-G
from EVT and display it on their surface via trogocytosis, which is
postulated to prolong intracellular signaling for an undefined
physiologic purpose [64]. In dNK subsets, dNK1 cells show the
greatest expression of KIRs (KIR2DS1, KIR2DS4, KIR2DL1, KIR2DL2,
and KIR2DL3), CD94/NKG2A, and LILRB1 compared with dNK2 and
dNK3, suggesting that it is dNK1 cells that particularly interact with
EVT. Specifically, dNKs regulate the depth of trophoblast invasion
and facilitate spiral artery transformation via the release of
cytokines including GM-CSF (granulocyte-macrophage colony-
stimulating factor), XCL1 (lymphotactin), and pro-angiogenic
factors, which directly act on blood vessels [13, 25, 65]. These
findings are confirmed in vitro, as dNK demonstrate enhanced
functions upon KIR2DS1 or KIR2DS4 cross-linking than upon
stimulation with by K562 targets or PMA and ionomycin, which are
good activators of pbNK cell functions [13, 25, 65].
Besides the receptor−ligand interactions, the regulation of
trophoblast on uNK cells involves a complex network of secreted
factors. Upon its establishment at the implantation site, tropho-
blast can modulate uNK migration, survival, proliferation, pheno-
type, and function by secreting a range of cytokines and
chemokines such as TGF-β, IL-6, CXCL8/ IL-8, CXCL12/ SDF1, and
CCL2/MCP1. IL-6 and CXCL8 secreted by EVTs can induce CCL14
and CXCL6 expression in endothelial cells. This crosstalk promotes
dNK cells and decidual macrophages infiltration to the early
remodeling decidual spiral arteriole wall [66].
Cytokines
Implantation and EVT invasion are accompanied by modulations of
molecular mediators of inflammation, such as prostaglandin E2
(PGE2), Tumor necrosis factor (TNF), IL-6, IL-1β, leukemia inhibitory
factor (LIF), and IFN-γ [67]. However, the absence of neutrophil
infiltration, which is the cellular hallmark of the acute inflammatory
response, clearly shows that the response of the decidualized
endometrium partially overlaps but does not fully recapitulate the
F. Wang et al.
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stereotypical inflammatory response that follows tissue injury. In
mice, IFN-γ produced by uNK cells is the key factor to remodel the
spiral arteries. PGE2 signaling increases vascular permeability and
activates NK cells, macrophages, and other regulatory immune cells
[68]. TNF synthesized by NK cells, T cells, macrophages, and DCs, and
by decidual stromal cells, trophoblast cells, and placenta can induce
MMP-9 production in uNK cells, which indirectly affects maternal
vascular remodeling [69]. TNF plays an important role in embryo
implantation, placentation, and pregnancy progression [70]. How-
ever, increased TNF is associated with miscarriage, fetal loss, pre-
eclampsia, preterm birth, and endometriosis [71]. TNF inhibitors are
readily available for the treatment of autoimmune conditions and
have been used in assisted reproductive technology [72]. TGF-β1
plays a significant role in embryo implantation, decidual angiogen-
esis, and EVT invasion [73]. TGF-β1 in the uterus is produced
predominately by Tregs, DCs, and epithelial cells [68, 73]. Both
humans and murine uNK cells express the receptor for TGF-β. TGF-β1
suppresses the expression of activating NK cell receptors such as
NKG2D and NKp30, but increases CD56 expression in human dNK
and pbNK cells [74, 75]. Furthermore, TGF-β1 can downregulate
IFNG/ VEGF expression in human dNK cells [75] and convert pbNK
cells into dNK cells in vitro [41].
Metabolites
Pregnancy involves metabolic adaptations. Concentrations of
bioactive molecules such as steroid hormones and micronutrients
change throughout gestation [76]. In human plasma samples,
steroid hormones including estriol-16-glucuronide, estrone 3-
sulfate, and progesterone increase over 50% during pregnancy,
while most lipids or lipid-like molecules, such as monoacylglycer-
ides, and lyso-phosphatidylcholines decrease. Most of these
metabolites originate from the adrenal cortex and gonads, and
return to baseline promptly postpartum [76]. The dS3 subset of
decidual stromal cells expresses genes such as CYP11A1 involved
in steroid biosynthesis [1]. Hormones are critically involved in a
successful pregnancy, and hormonal imbalance can lead to
serious pregnancy complications.
During early pregnancy, uNK cells accumulate and expand
significantly at the fetal–maternal interface, and this accumulation
may be related to the hormone-rich mucosal microenvironment
[77]. Human uNK cells express estrogen receptor (ER)β1, ER beta
cx/beta 2, and glucocorticoid receptor (GR), but not the estrogen
receptor α or progesterone receptors [78, 79]. The distribution of
murine uNK cells during early pregnancy is regulated by estrogen
and progesterone, and their effects can be abolished by specific
antagonism of their nuclear receptors [80]. Estrogen, especially
estradiol (E2), can directly promote uNK migration and secretion
of (C-C motif) ligand 2 (CCL2) to promotes vascular remodeling
[81]. Progesterone promotes human uterine stromal cells and
endothelial cells secreting chemokines, including CXCL8/IL-8,
CXCL10/IP-10, CXCL12/SDF-1, CX3CL1/Fractalkine, and CCL2/
MCP-1, which can recruit pbNK, dNK, and T cells to the uterus
during early pregnancy [52]. Besides, progesterone can stimulate
human endometrial stromal cells secreting IL-15 to promote uNK
self-renewal [82]. Progesterone reduces CD69 and IFN-γ expres-
sion induced by CpG and IL-12 in human uNK cells and mouse
splenic NK cells [79]. Some of the immunological effects of
progesterone are mediated by the progesterone-induced blocking
factor (PIBF). PIBF serum concentrations increase throughout
pregnancy and decrease before labor [83]. During spontaneous
miscarriage or preterm delivery, urinary and serum PIBF concen-
trations are lower than normal [84]. In mice, anti-PIBF monoclonal
antibody treatment or anti-progesterone treatment in the peri-
implantation period result in decreased PIBF+ dNK cells number
and increased splenic NK activity, together with impaired
implantation and increased resorption rates [85]. These data
suggest that the pregnancy-protective effect of the progesterone
and PIBF may be due to their inhibitory activity on NK cells. The
glucocorticoid prednisolone is reported to reduce dNK cell
concentrations in recurrent miscarriage and in patients who suffer
from repeated implantation failure and may have with high uNK
cell concentrations; however, small sample-size reports did not
reveal a significant beneficial effect of this treatment on
pregnancy outcomes [86, 87]. Endogenous glucocorticoids induce
PD-1 expression on spleen NK cells and reduce IFN-γ production in
mice upon viral infection [88], although both human and murine
NK cells display minimal PD-1 expression [89]. Human chorionic
gonadotrophin (hCG) is one of the first hormones synthesized by
the embryo and has immunomodulatory properties during
pregnancy [90]. hCG acts on many immune cells including uNK,
regulatory T (Treg) cells, B cells, DCs, macrophages, and
monocytes [90, 91]. uNKs do not express luteinizing hormone/
choriogonadotropin receptor, which is the classical hCG receptor
expressed by the endometrial surface. Instead, hCG regulates the
proliferation of uNKs through another receptor, the mannose
receptor (CD206) [92].
Besides hormonal changes, significant changes in glucose,
lipids, proteins, vitamins, and calcium metabolism also occur
during pregnancy [93]. At present, the effects of these changes on
uNK cells are unclear, although there is information available on
their effect on pbNK cells. For example, levels of vitamin D
increase significantly in maternal serum during pregnancy and
vitamin D is metabolized further into an active form of vitamin D,
1,25-dihydroxyvitamin D3 (1,25(OH)2D3). In addition to calcium
homeostasis and bone metabolism, 1,25(OH)2D3 exerts an
immunomodulatory effect on multiple immune cells including
NK cells, T cells, B cells, and macrophages in pregnancy [94]. 1,25
(OH)2D3 reduces pbNK-cell cytotoxicity and cytokine secretion in
women with recurrent pregnancy loss [95]. Vitamin D3 upregu-
lated protein 1 (VDUP1) is required for the development of mouse
NK cells [96]. Vitamin D3 may have an effect also on human dNK
cells as dNK cells express the vitamin D receptor [97].
Hypoxia
Hypoxia is a physiological feature of the uterus in early pregnancy.
Rodesch et al. [98] recorded that the endometrial average oxygen
tension (PO2) in the human endometrium was around 39.6 mm Hg
(5% O2) in pregnancies at 8–10 week’s gestation [98]. The PO2 in
the endometrium and placenta rises steeply between 10 and
12 weeks [99]. Cells use hypoxia-inducible factors (HIFs) to sense,
adapt, and respond to low oxygen. The stability and function of
transcription factor HIFα proteins (HIF-1α, HIF-2α, and HIF-3α
isoforms) are post-translationally regulated by hydroxylation.
Uterine expression of HIF-1α and HIF-2α is increased and up-
regulated by progesterone, and estrogen in early pregnant mice
[100]. HIFα regulates placental angiogenesis [101], luminal
epithelium detachment, and trophoblast cell differentiation and
invasion [102–104].
Local tissue oxygen tension performs as one of the key
physiological regulatory mechanisms for immune responses. In
murine spleen and lymph nodes, the level of exposure to hypoxia
was high in NK cells than in NKT, T, and B cells [105], indicating NK
cells may have a stronger ability to adapt to low oxygen
environment. Hypoxia may contribute to the phenotypic and
functional adaption of uNK to the uterus. In contrast to pbNK cells,
uNK cells have low cytotoxic ability, and secrete pro-angiogenic
factors. Hypoxia in the presence of TGF-β1 (1% O2) decreases
cytotoxicity and enhances VEGF-α production by human dNK cells
[106]. Hypoxia also impairs human pbNK cell cytotoxicity, cytokine
and chemokine secretion, and the expression of activating NK cell
receptors [107, 108]. Depletion of Hif1a in mouse NK cells or short-
term hypoxia does not affect NK cell maturation or receptor
repertoire. Similarly, splenic NK cell degranulation and IFN-γ
expression are not affected under hypoxia, when stimulated with
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ligands, cytokines, or PMA/ionomycin; however, these functions
were decreased in response to certain tumor cell lines [109].
Genetic or pharmacological ablation of Hif1a in NK cells mouse
and human NK cells results in elevated cytotoxicity and IFN-γ
expression in response to tumor cells [108].
Hypoxia improves lymphoid differentiation potentials of
lymphoid-primed multipotent progenitors (by HIF-1α) and pro-T/
NK cells (by HIF-2α) in vitro [110]. The hypoxic nature of the
uterine microenvironment raises the possibility that uNK cells are
derived in situ because hypoxia contributes to phenotypically and
functionally converting pbNK cells to uNK cells. Indeed, a
combination of hypoxia, TGF-β1, and demethylating agents
converts human pbNK cells to uNK-like cells [106], suggesting
that uNK may also derive from pbNK cells. Genes that are typically
upregulated in response to hypoxia (such as Ang and Hif3a) were
upregulated in mouse uILCs at gd9.5, compared with liver ILC,
indicating that uterine hypoxia microenvironment may affect
uILCs [9].
Overall, hypoxia may contribute to the phenotypic and
functional adaption of uNK cells to the uterus, and meanwhile,
uNK cells regulate vascular remodeling and subsequently
modulate oxygen delivery and trophoblast lineage decisions
[111]. The hypoxia affecting NK cell function might be dependent
on conditions in the microenvironment. For example, prolonged
exposure to hypoxia and other factors, such as inflammatory
cytokines, might drive HIFs stabilization and its functions [108].
The uterus must manage the stress of constant tissue
reorganization, cell division, and, upon implantation, hypoxia,
vascular remodeling, and trophoblast invasion. Peripheral NK cells
can sense stress during infection and cancer, for example through
NKG2D that binds stress-induced ligands (e.g., MICA, MICB, ULBP1-
3, MULT-1, or in mice, Rae-1). Whether uNK cells also sense stress
through NKG2D or other receptors is unknown. In pregnant mice,
NKG2D binds Rae-1 expressed on trophoblast and triggers IFN-γ
production by uNK cells [112]. In pregnant rats, lack of uNK cells
affects trophoblast lineage decision with consequent deeper
trophoblast invasion in response to hypoxia [102]. In non-
pregnant women who are pharmacologically treated to stop
excessive bleeding through progesterone blocking, the endome-
trial arteries display thick walls and reduced vessel lumens. The
endometrial vascular phenotype of anti-progesterone-treated
women is similar to that found in the decidua of NK-deficient
pregnant mice. Interestingly, anti-progesterone treatment inter-
feres with IL-15 production by endometrial stromal cells, leading
to uNK cell deficiency in women [113]. Therefore, uNK cells are
responsible for arterial remodeling both in the non-pregnant
endometriam and in the decidua.
First pregnancy and beyond
In humans, first-time pregnant women (nulliparous) are exposed
to a greater risk of poor placentation and placental development
than women experiencing repeated pregnancies [114]. A subset of
human NKG2Chigh dNK cells, which seem to “remember”
pregnancy, may facilitate subsequent pregnancies by enhanced
IFN-γ and VEGF production [18]. Transcriptome and epigenetic
analysis revealed that these “pregnancy-trained” dNK cells are
indeed a unique and tissue-specific population [18]. Pregnancy-
trained human dNK cells most closely resemble dNK1 cells with
higher expression of NKG2C, LILRB1, and KIR [1, 18]. ‘Priming’ of
dNK1 subsets during the first pregnancy may make them respond
more effectively in subsequent pregnancies [1]. Murine dILC1
expressing CXCR6 expand in second pregnancies indicating they
may act as memory cells [9]. Cytokines IL-12, IL-15, and IL-18 and
NK cell receptors CD16, CD2, and NKG2C can induce memory-like
pbNK cells [115, 116]. Epigenetic imprinting and metabolomic
programming of memory-like pbNK cells occur in chronic human
CMV infection [117]. It is unknown whether pregnancy-trained
uNK cells are relatable to cytokines- or CMV-induced memory-like
pbNK cells; however, specific receptor−ligand interactions,
inflammatory cytokines, and hypoxia in the unique uterine
microenvironment may well contribute to the generation of
memory-like cells among uNK subsets.
BIOLOGY OF DISEASE
A careful synergy of physiological signaling is required to guide
proper implantation, intrauterine development, and balancing of
fetal−maternal immune interactions for successful placentation
and pregnancy [118]. Disruption of these tightly regulated
processes can result in life-threatening complications for mom
and baby [119]. In this section, we briefly summarize potential uNK
cell roles in pregnancy complications.
Great obstetrical syndromes
Defective deep placentation due to inadequate spiral artery
transformation is found in a host of pregnancy complications
termed ‘Great Obstetrical Syndromes’ (GOS). Syndromic in nature,
GOS are frustratingly complex to predict and prevent due to their
long preclinical period, multiple aetiologies, and interactions
between maternal and fetal genomes along with the environment
[120]. Specifically, preeclampsia (PE), FGR, preterm labor, preterm
premature rupture of membranes, recurrent spontaneous abor-
tion (RSA), and abruption placentae are all GOS responsible for
maternal and perinatal morbidity [121]. All GOS are thought to
originate from defective EVT invasion causing insufficient arterial
remodeling, with consequent disruptively high blood flow speed
but reduced gas and nutrient exchanges, resulting in placental
stress and damage.
Although the exact pathophysiology mechanism underlying the
GOS is undefined, the immune system and uNK cells may be part
of it. Figure 2 illustrates the main events leading to pre-eclampsia.
Pre-eclampsia refers to the onset of hypertension and proteinuria
after 20 weeks of gestation, occurring in 2–8% of the pregnancies
as a consequence of abnormal placentation and subsequent
maternal vascular dysfunction. Progression to the eclamptic phase
can be fatal and requires immediate delivery of the placenta, and
therefore the baby, to resolve [122]. PE and FGR are intimately
connected as high resistance vessel blood flow and marked pro-
inflammatory secretion in the uterine microenvironment found as
a consequence of PE often cause FGR. Infants born with a birth
weight below the 10th percentile termed small for gestational age
(SGA), can be pathological due to chromosomal abnormalities,
intrauterine infections, or FGR. Inadequate spiral artery remodel-
ing from defective placentation is the primary etiology of FGR, in
which forced elevation in umbilical artery pressure cause placental
endothelial decompensation from blood spurting and increased
fetal middle cerebral artery blood flow (a phenomenon known as
brain sparing). Ultimately, FGR manifests as clinically recognized
asymmetric head to abdominal circumference and has been
associated with behavioral/cognitive consequences [123].
The immunogenetics of PE and other pregnancy complications is
reviewed elsewhere [60, 61] and summarized in Fig. 3. Changes in
the uterine microenvironment have been described in pregnancy
complications. Compared with normal pregnancy subjects, Tregs are
decreased both in placental bed and the circulation in women with
pre-elampsia [124], while pro-inflammatory Th17 cells and cytokines
IFN-γ and IL-4 are increased [125]. Additionally, enhanced activation
of M1 macrophages occurs [126]. dNK cells can regulate other
immune cells, including induction of Tregs and suppressing Th17
cells [127]. In PE, the phenotypes, cytotoxicity, and production of
cytokines and angiogenic factors by NK cells are changed [128]. For
example, proposed as a potential diagnostic tool, women with PE
display an attenuation of the relative proportion of CD56bright/
NKp46+ pbNKs and elevation of CD56+/NKp44+ pbNKs, in which
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the former persists from the onset of PE until delivery [128]. Despite
these reported associations, pbNKs are not representative of the NK
cells at the fetal-maternal interface and therefore pbNK findings
cannot be straightforwardly extrapolated to uNKs [127, 129, 130].
Reported associations of uNK cell decline or elevation with PE and
FGR are debatable [131–135]; however inappropriate uNK activity
seems to be associated with the incidence of PE and FGR [65].
Increased number of cytotoxic NK cells in PE patients has also
been reported [127]. Women with PE were also found to display
elevated expression of perforin, and granzyme B compared on
both pbNKs and uNKs [135, 136]. Interestingly, these molecules
are markedly more elevated in early rather than late-onset PE
women [135]. In PE mothers, overly cytotoxic uNKs are postulated
to target first-trimester trophoblast for apoptosis and inhibit their
spiral artery invasion and migration [135]. Mimicking of PE via a
reduced uterine perfusion pressure (RUPP) model revealed
improved FGR and inflammation upon depletion of NKs from
the uterine microenvironment [137, 138]. These results suggest
that cytolytic uNKs contribute to hypertension, FGR, and
inflammation in response to placental ischemia [138].
VEGF-C, a pro-angiogenic factor produced by uNKs, is less
expressed in women with PE and FGR [139]. Fu and colleagues
suggest that growth-promoting factors osteopontin, pleitrophin,
and osteoglycin, which are secreted by CD49a+ Eomes+ uNKs in
both humans and mice, are implicated in FGR prevention.
Adoptively transferred, these cells re-established an appropriate
uterine microenvironment and reversed impaired fetal growth in
the Nfil3−/− mouse model of FGR [63]. In line with these findings,
CD49a+ PBX1+ uNKs, which promote pleiotrophin and osteoglycin
transcription in humans and mice were recently found to be
required for optimal fetal growth as reduced or complete loss of
PBX1 expression is associated with FGR and RSA [140]. Further-
more, TNF modulatory agents, such as Etanercept, may play a role
as a potential therapeutic for PE as TNF-α blockade ameliorated
hypertension and reduced mitochondrial ROS and cytolytic NK
counts in a RUPP rat model [141]. IL-17 is a candidate mediator of
PE as IL-17 blockade in a RUPP model improves the placental and
fetal weight, placental VEGF expression. IL-17 blockade also
attenuates TNF-α, MIP-3α, and placental cNK cytolytic activity
and counts [142]. Emerging evidence from cord blood samples in
PE mothers reveals fetal NKs are also dysregulated as there is a
higher ratio of effector to regulatory pbNKs [143, 144]. Some
reports show loss of uNKs in PE pregnancies complicated with
FGR, while only a small uNK decline is seen in PE and normal
pregnancies [131]. Genetic inactivation of PI3K p110δ—a crucial
molecule for intracellular signaling in leukocytes—causes reduced
Fig. 3 KIR on maternal dNKs and HLA-C on fetal EVT affect
pregnancy outcomes.
Fig. 2 The pathophysiology of Pre-Eclampsia.
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uterine arterial remodeling associated with lower uNK cell
production of IFN-γ, which subsequently lead to FGR in a mouse
model [145]. Incidence of PE is also associated with variants of
endoplasmic reticulum aminopeptidase 1 and 2 (ERAP1/2) [146],
receptors present in the placenta involved in the regulation of
blood pressure, angiogenesis, immune recognition [147],
modulation of NK cell and CD8+ T responses [148, 149], as well
as recruitment of cytotoxic pbNK cells [146]. Perhaps the steady
circulation of these cytotoxic pbNKs contributes to the clinical
manifestation of PE via dysregulating the innate immune response
and aggravating the uterine microenvironment.
RSA and recurrent implantation failure (RIF) are largely
idiopathic pregnancy disorders that are distressing and pose
serious threats to the mother and fetus. The causes of RSA and RIF
are complicated, including chromosomal abnormalities, uterine
structure abnormalities, endocrine causes, and infections. The role
of immune cells in RSA and RIF is under scrutiny. For example, uNK
cells may indirectly ‘sense’ embryos by targeting senescent
decidual cells. Medium-conditioned embryos that fail to implant,
but not successful embryos, inhibit uNK-cell-mediated killing of
senescent decidual cells [150]. This suggests that uNK cells
contribute to the selection of healthy embryos. Interestingly, pbNK
cells also have the ability to detect senescent cancer cells through
receptors NKG2D and DNAM-1 [151]. RSA and RIF are associated
with an imbalanced and possibly inflamed uterine immune
microenvironment. However, the main obstacle to determine
the cellular and molecular mechanism leading to RSA and RIF is
that investigations are inevitably conducted after the pathology
has occurred and therefore distinguishing causes from conse-
quences is challenging. Nevertheless, comparative scRNA-
sequence analysis of pathological and normal utero-placental
tissues may shed further light on the potential mechanisms [3].
Stillbirth is the loss of a fetus in utero. The definite cause of
stillbirth remains elusive; however, besides its association with PE
due to placental vascular dysplasia [152], there is evidence
indicative of NK cell involvement. Expression of RCAS1, a type II
membrane protein expressed in the uterine endometrium and
EVTs known to contribute to maternal immune tolerance, was
found to be low in placental tissue of women following stillbirth
[153]. Also, scaffolding protein Grb2-associated binding protein 3
(Gab3) was recently discovered to be critical for uNK cell
expansion, spiral artery remodeling, and appropriate limiting of
trophoblast invasion in mice [154]. Notably, Gab3 murine knock-
out resulted in maternal hemorrhage and stillbirth.
Infections
How maternal uNK cells and other innate and adaptive immune
cells control infection while promoting fetal development is not
fully understood. We have reviewed the role of NK cells in
infection during pregnancy elsewhere [8]. There is evidence that
uNK and other immune cells prevent the spreading of pathogens
to the fetus. For example, dNKs display an elegant and unique
mechanism to control Listeria monocytogenes through the
antimicrobial peptide granulysin. Granulysin, stored in intracellular
granules, can transfer to infected EVTs via nanotubes to selectively
kill intracellular Listeria, without killing the infected EVTs [155].
Here we take human cytomegalovirus (HCMV) as an example to
summarize the interactions between intrauterine infection and
uNK cells during pregnancy.
HCMV is the most common cause of congenital virus infection,
passing from the maternal bloodstream through the placenta to
infect the fetus and leading long-term consequences. Around 1
out of 200 babies is born with CMV and about 20% of congenital
cases result in serious neurodevelopmental sequelae including
hearing and vision loss, seizures, motor delay, intellectual
disability, and microcephaly [156]. HCMV infection is also
associated with IUGR and placental dysfunction [157]. HCMV
infections during pregnancy add to the high occurrence of
miscarriage, pre-eclampsia, and preterm birth [158, 159]. Currently,
no HCMV vaccines are licensed for clinical use, no reliable prenatal
markers for congenital disease are identified, and no prenatal
antiviral treatments are available [118].
HCMV infection induces specific changes in the uterine
environment during pregnancy. HCMV replicates consistently in
decidual stromal cells and epithelial cells of endometrial glands,
which results in inflammation and impaired function, and soluble
molecule secretion [160]. HCMV can spread from the decidua to
chorionic villi in early gestation and attenuate trophoblast
invasion and differentiation [157]. Congenital viral infection of
the placenta leads to pathological changes, including the
development of avascular villi, edema, calcification, hypoxia, and
inflammation, and thus causes deleterious effects including
placental insufficiency, stillbirth [158], and IUGR [157]. Infections
trigger a series of immune microenvironment changes such as
activation of the complement system, innate and adaptive
immune cells, and secretion of pro-inflammatory cytokines.
HCMV-infection modulates uNK cell receptor repertoire and
secretory profile [160]. CD56, KIR2DL1, KIR2DL4, and ILT2 decrease
while NKp44, NKG2C increase in dNK cells, which also acquire
CD16. HCMV-infection also modulates cytokine and chemokine
secretion by dNK cells, and increases Granzyme B, which may
contribute to eliminating HCMV by cytotoxicity [160]. Acute HCMV
infection triggers selective expansion of CD57+ NKG2Chi pbNK
populations, affecting the expression of their inhibitory receptor
[161]. However, this expansion has not been observed in uNK cells.
uNKs accumulate at the site of HCMV-infected tissue and co-
localize with infected cells [160, 162]. uNK expressing the
activating KIR2DS1 receptor display increased cytotoxicity toward
HCMV-infected DSCs, especially when DSCs express the cognate
HLA-C2 ligand. KIR2DS1 expression in uNK is associated with
greater intracellular content of perforin, granzyme B, and
granulysin [20]. Lysis of HCMV-infected dSC by uNKs could limit
viral spread to the fetoplacental unit [163]. While pbNKs can
degranulate toward HCMV-infected EVT in vitro, it remains
uncertain whether they can flux into the decidua in vivo.
Interestingly, even if uNKs can kill HCMV-infected DSCs, EVT are
more resistant to NK cell cytotoxicity, which could be due to HLA-
G expression on EVT [164]. EVT may possess an independent
HCMV defense mechanism, such as miRNA or cell-surface death
receptor expression. HCMV targets HLA-C for downregulation in
order to limit trophoblast invasion, evade viral peptide presenta-
tion on maternal T cells [165], and reduce activation of both HLA-C
restricted T cells and KIR2DS1+ uNK [166].
Endometriosis and endometrial cancer
Endometriosis is a condition of unknown etiology and unclear
pathogenesis that may affect up to one in ten women in
reproductive age with pain, morbidity, and, in some cases,
infertility. Several studies have reported that reduced NK cell
activity is associated with endometriosis [167]. Recent studies
have attempted to assess the correlation of certain combinations
of KIR and HLA-C genes with endometriosis [168]. It is reasonable
to postulate that reduced NK cell activity may facilitate the extra
endometrial growth, which underlies endometriosis, but the
mechanisms are unclear. In a case-control study of a small
number of patients and controls, the percentage of peritoneal NK
cells expressing the inhibitory receptor CD94/NKG2A+ NK cells
was higher in patients with endometriosis [169]. This suggests a
role for CD94/NKG2A and its cognate ligand HLA-E in suppressing
NK cell activity in these patients.
Endometrial cancer (EC) is the most common gynecological
cancer and the fourth most common malignancy in females. Parity
may be negatively associated with EC risk [170], suggesting that
modulation of estrogen and progesterone levels affect suscept-
ibility. The presence of CD8+ cytotoxic T cells within the tumor
microenvironment and loss of HLA class I expression correlates
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positively and negatively, respectively, with disease outcomes and
survival of patients with EC. The presence of NK cells also
associates with better outcomes when HLA-E is upregulated, while
maintenance of normal HLA-E expression associates with the
worst outcomes. HLA-E has a greater affinity for the inhibitory
NKG2A rather than the activating NKG2C receptor on NK cells. One
possibility to explain the beneficial effect of high HLA-E expression
and NK cell is that an increase in HLA-E may saturate NKG2A, thus
shifting the interaction toward NKG2C and away from NK
inhibition to promote tumor lysis [171].
RECENT DEVELOPMENTS
Interest in the topic of this review is growing rapidly. Access to
unique human samples and data, availability of new technology,
including multiple “-omics”, and new mouse models are helping
to expand our knowledge of the uterine microenvironment and its
NK cells. Using a combination of mouse models, micro-CT scans,
and micro-dopplers in mice, we have recently shown that the
conserved CD94/NKG2A inhibitory receptor is required to educate
mouse uNK cells. Indeed, with a functional Qa1-NKG2A pathway,
the uterine micro-environment educates uNK cells effectively to
mediate the necessary vascular changes in the uterus that
ultimately help fetuses to grow symmetrically and sustain normal
brain development [56]. In the same study, we showed that the
NKG2A pathway is linked to pre-eclampsia in a meta-GWAS
analysis of over 150,000 human pregnancies [56].
Using single-cell profiling, it was recently shown that the
decidual micro-environment of patients with recurrent pregnancy
loss (RPL) is different from that of normal control pregnancies. One
of these differences is that a subset of uNK cells that specializes in
supporting fetal growth is reduced in patients. Despite the
inevitable complications of comparing a pathological sample with
a healthy one, this study helps deciphering the decidual
microenvironment with the view of improving diagnosis and
therapy of RPL [172].
Also using a combination of mouse models and human
endometrial samples, plus uterine tissue of either women who
had undergone uterine transplant or monozygotic twins, it was
shown recently that endometrial NK cell differentiation is, at least
in part, a genetically determined process driven by IL-15. This
process happens continuously and in response to both monthly
endometrial regeneration and pregnancy [21].
The importance of certain variants of immune system genes HLA-C
and KIR in creating a uterine micro-environment conducive to healthy
fetal growth was confirmed recently in an elegant humanized mouse
model. Fetal growth was reduced in pups of transgenic females that
express a specific variant of the strongly inhibitory human KIR2DL1
receptor on all their NK cells, but only when sires were males
expressing the cognate human HLA-C ligand [173]. This supports a
working model in which too much inhibition of uNK cells leads to
poor fetal growth [174], a model based on human genetic
epidemiology evidence [60].
CONCLUDING REMARKS
From menarche to menopause the uterus remodels its mucosa
every month in response to hormones. During the course of
pregnancy and upon blastocyst implantation, the uterus under-
goes even more dramatic changes including trophoblast invasion,
and vascular remodeling, culminating in the formation of the
placenta. These adaptations are accompanied by changes in
tissue-resident immune cell populations, hypoxia, and metabolic
adaptations. The unique microenvironment of the uterus during
pregnancy remodels and adapts the phenotype and function of
uNK cells. At the same time, uNK cells promote arterial integrity,
decidualization, EVTs invasion, spiral arterial remodeling, early
placental formation, and fetal growth. Determining the
mechanisms underlying these adaptations will help understand
the causes of major pregnancy complications.
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